![Aaron Goodman: My prediction (American Society of Hematology 2023)](https://oncodaily.com/pub/uploads/2023/07/Aaron-Goodman-e1723462958200-1280x1261.jpeg)
Photo from Aaron Goodman/X
Dec 9, 2023, 16:37
Aaron Goodman: My prediction (American Society of Hematology 2023)
Aaron Goodman shared a post on X/Twitter:
“My prediction is the plenary session at American Society of Hematology in 2033 will be 10 drugs vs 9 drugs in myeloma end point Minimal Residual Disease (MRD). IKRd vs KRd in newly diagnosed multiple myeloma.
For details, click here.
Source: Aaron Goodman/X
Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.